Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Theravance Biopharma is set to lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.  | Theravance Biopharma will lay off 50% of ...

RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS ...

The biopharmaceutical company said Tuesday that its restructuring includes the complete wind down of its research and development organization, as well as a roughly 50% decrease in general and ...

Theravance Biopharma said it is chopping its workforce by 50% and launching a review of strategic alternatives designed to maximize shareholder value, after its sole rare disease pipeline candidate, ...

UB researchers Andrew Rodgers and Jeffrey Lackner co-authored an editorial about a study on how some patients with pain may ...

The progressive loss of function and structure of neuronal cells is a process that falls under the name "neurodegeneration." Regardless of their etiology, ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early ...

A recent brain imaging study reveals that attention deficit hyperactivity disorder consists of at least two distinct physical subtypes. This discovery suggests that patients may eventually benefit ...

Purdue’s strategic initiatives, which include leveraging the university’s extensive technological and computational environment and tackling complex challenges at the intersection of human, animal and ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

A new study found Spinraza treatment restores a key amino acid called taurine in SMA type 1, which may improve clinical outcomes in children.